Clinical efficacy of beta-lactam/beta-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR)

Imagem de Miniatura
Arquivos
art_GUDIOL_Clinical_efficacy_of_betalactambetalactamase_inhibitor_combinations_for_the_2017.PDF (620.59 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2017
Editora
BMJ PUBLISHING GROUP
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
GUDIOL, C.
ROYO-CEBRECOS, C.
TEBE, C.
AKOVA, M.
ALVAREZ, R.
CALLE, G. Maestro-de la
CANO, A.
CERVERA, C.
CLEMENTE, W. T.
Autor de Grupo de pesquisa
BICAR Study Grp
Editores
Coordenadores
Organizadores
Citação
BMJ OPEN, v.7, n.1, article ID e013268, 6p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction Bloodstream infection (BSI) due to extended-spectrum -lactamase-producing Gram-negative bacilli (ESBL-GNB) is increasing at an alarming pace worldwide. Although -lactam/-lactamase inhibitor (BLBLI) combinations have been suggested as an alternative to carbapenems for the treatment of BSI due to these resistant organisms in the general population, their usefulness for the treatment of BSI due to ESBL-GNB in haematological patients with neutropaenia is yet to be elucidated. The aim of the BICAR study is to compare the efficacy of BLBLI combinations with that of carbapenems for the treatment of BSI due to an ESBL-GNB in this population. Methods and analysis A multinational, multicentre, observational retrospective study. Episodes of BSI due to ESBL-GNB occurring in haematological patients and haematopoietic stem cell transplant recipients with neutropaenia from 1 January 2006 to 31 March 2015 will be analysed. The primary end point will be case-fatality rate within 30days of onset of BSI. The secondary end points will be 7-day and 14-day case-fatality rates, microbiological failure, colonisation/infection by resistant bacteria, superinfection, intensive care unit admission and development of adverse events. Sample size The number of expected episodes of BSI due to ESBL-GNB in the participant centres will be 260 with a ratio of control to experimental participants of 2. Ethics and dissemination The protocol of the study was approved at the first site by the Research Ethics Committee (REC) of Hospital Universitari de Bellvitge. Approval will be also sought from all relevant RECs. Any formal presentation or publication of data from this study will be considered as a joint publication by the participating investigators and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE). The study has been endorsed by the European Study Group for Bloodstream Infection and Sepsis (ESGBIS) and the European Study Group for Infections in Compromised Hosts (ESGICH).
Palavras-chave
ESBLs, Bacteraemia, Neutropenia, beta-lactam, beta-lactamase inhibitors, haematologic stem cell transplant
URI
https://observatorio.fm.usp.br/handle/OPI/18842
Referências
  1. Albiger B, 2015, EUROSURVEILLANCE, V20, P45
  2. Diaz MA, 2010, J CLIN MICROBIOL, V48, P2840, DOI 10.1128/JCM.02147-09
  3. Friedman ND, 2002, ANN INTERN MED, V137, P791
  4. Gudiol C, 2010, J ANTIMICROB CHEMOTH, V65, P333, DOI 10.1093/jac/dkp411
  5. Gutierrez-Gutierrez B, 2016, ANTIMICROB AGENTS CH, V60, P4159, DOI 10.1128/AAC.00365-16
  6. Ha YE, 2013, INT J ANTIMICROB AG, V42, P403, DOI 10.1016/j.ijantimicag.2013.07.018
  7. Harris PNA, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0055-6
  8. Hauck C, 2016, CLIN MICROBIOL INFEC, V22, P513, DOI 10.1016/j.cmi.2016.01.023
  9. Hoban DJ, 2010, ANTIMICROB AGENTS CH, V54, P3031, DOI 10.1128/AAC.01808-09
  10. Hsih-Yeh T, 2014, DIAGN MICROBIOL INFE, V80, P222, DOI [10.1016/j.diagmicrobio.2014.07.006, DOI 10.1016/J.DIAGMICROBIO.2014.07.006]
  11. Hussein K, 2009, INFECT CONT HOSP EP, V30, P666, DOI 10.1086/598244
  12. Kim SH, 2013, ANN HEMATOL, V92, P533, DOI 10.1007/s00277-012-1631-y
  13. Klastersky J, 2000, J CLIN ONCOL, V18, P3038
  14. Kumarasamy KK, 2010, LANCET INFECT DIS, V10, P597, DOI 10.1016/S1473-3099(10)70143-2
  15. Ng TM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153696
  16. Ofer-Friedman H, 2015, INFECT CONT HOSP EP, V36, P981, DOI 10.1017/ice.2015.101
  17. Patel G, 2008, INFECT CONT HOSP EP, V29, P1099, DOI 10.1086/592412
  18. Pitout JDD, 2008, LANCET INFECT DIS, V8, P159, DOI 10.1016/S1473-3099(08)70041-0
  19. Retamar P, 2013, ANTIMICROB AGENTS CH, V57, P3402, DOI 10.1128/AAC.00135-13
  20. Rodriguez-Bano J, 2008, EXPERT REV ANTI-INFE, V6, P671, DOI 10.1586/14787210.6.5.671
  21. Rodriguez-Bano J, 2012, CLIN INFECT DIS, V54, P167, DOI 10.1093/cid/cir790
  22. Shiber S, 2015, J ANTIMICROB CHEMOTH, V70, P41, DOI 10.1093/jac/dku351
  23. Tamma PD, 2015, CLIN INFECT DIS, V60, P1319, DOI 10.1093/cid/civ003
  24. Trecarichi EM, 2009, J INFECTION, V58, P299, DOI 10.1016/j.jinf.2009.02.002
  25. Tumbarello M, 2012, CLIN INFECT DIS, V55, P943, DOI 10.1093/cid/cis588
  26. Vardakas KZ, 2012, J ANTIMICROB CHEMOTH, V67, P2793, DOI 10.1093/jac/dks301
  27. von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
  28. [Anonymous], 1995, OFFICIAL J L, V281

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/47